
Senestech, Inc. (SNES) reported its quarterly financial results for the period ended June 30, 2026. The company’s revenue was $X million, a decrease of Y% compared to the same period last year. Net loss was $Z million, or $W per share, compared to a net loss of $X million, or $Y per share, in the same period last year. The company’s cash and cash equivalents decreased to $X million, and its total assets decreased to $Y million. The company’s management discussed the financial results in the MD&A section, highlighting the challenges faced by the company and the steps being taken to address them. The company also disclosed certain risk factors and other information in the report.
Financial Performance Overview
SenesTech, a company focused on developing proprietary pest management technologies, has transformed from a research-focused organization into a revenue-driven company over the past year. The company’s current product offerings are centered around rat and mouse population management, including Evolve and ContraPest.
SenesTech’s strategy is focused on three key priorities: (1) strengthening its e-commerce business to build the Evolve brand, educate the market, and establish credibility for a new category of pest management products; (2) expanding its direct business-to-business (B2B) operations through a professional sales organization targeting specific vertical markets for both Evolve and ContraPest; and (3) increasing its market opportunity through strategic partnerships, new products, and value-added services.
During the quarter ended June 30, 2026, the company made meaningful progress executing this strategy. Key highlights include:
Revenue and Profit Trends
SenesTech’s sales, net of discounts and promotions, were $770,000 for the second quarter of 2026, compared to $625,000 for the second quarter of 2025 - a 23% increase. For the six months ended June 30, 2026, sales were $1.3 million, compared to $1.1 million in the same period of 2025 - a 14% increase.
The increase in sales was primarily driven by higher sales of the company’s Evolve product offerings, reflecting continued growth in its e-commerce sales channels. Evolve represented approximately 86% of second quarter 2026 revenues, compared to 83% in the second quarter of 2025, and 85% of revenues for the six months ended June 30, 2026, compared to 81% in the same period of 2025.
The increase in Evolve sales was partially offset by lower ContraPest sales, which primarily occur through the company’s B2B sales channel. B2B sales were impacted by personnel turnover within the sales and marketing organizations during the first half of 2026, but SenesTech expects an increase in B2B sales, including increased ContraPest sales, as the transition is now complete.
Cost of sales was $203,000, or 26.4% of net sales, for the second quarter of 2026, compared to $216,000, or 34.6%, for the second quarter of 2025. For the six months ended June 30, 2026, cost of sales was $358,000, or 28.3% of net sales, compared to $388,000, or 35.0%, for the same period of 2025.
Gross profit for the second quarter of 2026 was $567,000, representing a margin of 73.6%, compared to $409,000, or 65.4%, in the second quarter of 2025. Gross profit for the six months ended June 30, 2026 was $905,000, representing a margin of 71.7%, compared to $722,000, or 65.0%, for the same period of 2025. The improvement in gross margins was primarily due to the transition to selling directly on Amazon, which began in February 2026 and was completed during the second quarter.
Strengths and Weaknesses
Strengths:
Weaknesses:
Outlook and Future Prospects
SenesTech believes its integrated strategy of building consumer awareness, expanding commercial sales, and offering differentiated products and services positions the company for sustainable long-term growth. The operational progress achieved during the quarter, combined with continued commercialization investments, reinforces management’s confidence in the execution of its strategy.
However, the company will require additional financing to fund its ongoing operating losses and growth initiatives. Based on its current operating plan, SenesTech believes its cash and cash equivalents as of June 30, 2026, together with current revenues and operating expense levels, will be sufficient to fund operations through the end of the first quarter of fiscal 2027.
To extend its cash runway and achieve profitability, the company will need to continue growing revenues, reducing operating expenses, or obtaining additional financing through equity issuances, debt financings, strategic partnerships, or other external sources. There can be no assurance that such financing will be available on acceptable terms, if at all. Failure to obtain additional capital could have a material impact on the company’s business, results of operations, and financial condition.
Overall, SenesTech has made significant progress in executing its commercialization strategy, as evidenced by improved financial performance and operational milestones. However, the company’s long-term success will depend on its ability to achieve sustainable revenue growth, control costs, and secure the necessary financing to fund its operations and growth initiatives until it reaches profitability.